Prof Wee Joo Chng speaks to ecancer about his interactive session at the virtual Myeloma Knowledge Exchange (MyKE Myeloma) 2021 meeting on cases of high-risk/MRD positive and standard-risk/MRD negative newly diagnosed multiple myeloma (NDMM).

He starts by explaining the interactive format of the session before discussing the distinction between high-risk and standard-risk NDMM patients.

Prof Chng talks about the identification of high-risk patients, how to then approach their treatment and the future of treatment for these patients. He suggests that now is a good time to re-establish a set of criteria that can be uniformly applied to determine risk.

He discusses MRD-negative response as a key treatment objective and the currently unanswered questions around 'MRD adapted treatment' in terms of dose intensification or potency. He concludes by discussing his personal approach to NDMM patients.